Concorrente brasileiro do Ozempic chega �s farm�cias a partir de junho por R$ 452 a caneta
AI Summary
The Brazilian pharmaceutical company EMS is set to release Ozivy, a diabetes type 2 treatment based on semaglutide, starting June 15th, priced at R$ 452 per pen. Ozivy enters the market as a competitor to the popular diabetes drug Ozempic, offering an alternative to Brazilian patients. This development is significant as it could provide more affordable options for diabetes management in Brazil, potentially improving patient access and outcomes.
Original Source
Read the full article at Redir →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.